About Anbio Biotechnology Class A Ordinary Shares
https://www.anbio.comAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
CEO
Michael Lau
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Instruments & Supplies
Sector Healthcare
Went public February 19, 2025
Full time employees 27
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $1.43 B
52w High $55.65
52w Low $5.18
P/E 623
Volume 43.95K
Outstanding Shares 43.89M
About Anbio Biotechnology Class A Ordinary Shares
https://www.anbio.comAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $5.01M ▲ | $945.21K ▼ | $4.15M ▲ | 82.84% ▲ | $0.09 ▲ | $4.15M ▲ |
| Q4-2024 | $2.53M ▼ | $3.87M ▲ | $-1.32M ▼ | -52.4% ▼ | $-0.03 ▼ | $-1.32M ▼ |
| Q2-2024 | $6.32M ▲ | $337.5K ▼ | $3.89M ▲ | 61.48% ▲ | $0.09 ▲ | $3.89M ▲ |
| Q4-2023 | $3.95M ▲ | $1.11M ▲ | $792.93K ▼ | 20.07% ▼ | $0.02 ▼ | $796.47K ▼ |
| Q2-2023 | $3.31M | $406.06K | $1.64M | 49.7% | $0.04 | $1.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $15.76M ▲ | $32.49M ▲ | $153.92K ▼ | $32.34M ▲ |
| Q4-2024 | $11.76M ▲ | $18.92M ▼ | $1.73M ▲ | $17.19M ▼ |
| Q2-2024 | $10.31M ▲ | $18.94M ▲ | $527.75K ▼ | $18.42M ▲ |
| Q4-2023 | $9.69M ▼ | $15.81M ▲ | $993.06K ▼ | $14.82M ▲ |
| Q2-2023 | $10.56M | $15.43M | $1.34M | $14.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2024 | $-1.32M ▼ | $1.6M ▲ | $215.57K ▲ | $-248.89K ▼ | $0 | $1.6M ▲ |
| Q2-2024 | $3.89M ▲ | $647.54K ▲ | $149.34K ▼ | $-124.14K ▼ | $0 | $647.54K ▲ |
| Q4-2023 | $792.93K ▼ | $-1.33M ▼ | $160.7K ▼ | $230.08K ▲ | $0 | $-1.33M ▼ |
| Q2-2023 | $1.64M | $2.3M | $1.71M | $-276.41K | $0 | $2.3M |
CEO
Michael Lau
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Instruments & Supplies
Sector Healthcare
Went public February 19, 2025
Full time employees 27
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0